Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group

Minimal residual disease (MRD) is an independent predictor of relapse risk in children with leukemia and is widely used for risk‐adapted treatment. This article summarizes current evidence supporting the use of MRD, including clinical significance, current international clinical practice, impact sta...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2016-06, Vol.63 (6), p.973-982
Main Authors: Athale, Uma H., Gibson, Paul J., Bradley, Nicole M., Malkin, David M., Hitzler, Johann
Format: Article
Language:English
Subjects:
acute lymphoblastic leukemia
acute myeloid leukemia
Child
Hematology
hematopoietic stem cell transplantation
Humans
Leukemia
Leukemia - pathology
Leukemia - therapy
leukemic relapse
Medical Oncology - standards
minimal residual disease
Neoplasm, Residual - diagnosis
Neoplasm, Residual - therapy
Oncology
pediatric
Pediatrics
Pediatrics - standards
prognostication
risk stratification
Standard of Care
Working groups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Minimal residual disease (MRD) is an independent predictor of relapse risk in children with leukemia and is widely used for risk‐adapted treatment. This article summarizes current evidence supporting the use of MRD, including clinical significance, current international clinical practice, impact statement, and recommended indications. The proposed MRD recommendations have been endorsed by the MRD Working Group of the Pediatric Oncology Group of Ontario and provide the foundation for a strategy that aims at equitable access to MRD evaluation for children with leukemia.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.25939